Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Considerations for TKI choice in frontline and R/R CML

Jorge Cortes • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Jorge Cortes, MD, Augusta University, Augusta, GA, outlines some of the factors that play a role in choosing a tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) in the frontline and relapsed/refractory (R/R) settings, including the goal of therapy, comorbidities, drug toxicities, schedule of administration, and mutations. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.

More from Jorge Cortes

2:12
Key emerging trials in CML and the importance of improving treatment-free remission rates
Jorge Cortes • 7 Sep 2023
2:09
Social determinants of health & their impact on patients with hematological malignancies
Jorge Cortes • 7 Sep 2023
1:57
Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status
Jorge Cortes • 7 Sep 2023
2:21
Exciting updates in the field of CML: disease pathophysiology & novel agents
Jorge Cortes • 7 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals